A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors

← catalyst calendar

NCT07077434 · readout in 153 d

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

32estimated

Sites

Countries

China, Japan

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-10-15

actual

When the study began enrolling

Primary completion

2027-01-19

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-01-19

estimated

The whole study's end, after follow-up

First posted

2025-07-22

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-03

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Advanced Solid Tumors

Intervention

Drug: BMS-986504 — also filed as MRTX1719